Trial Profile
Phase I/II Prospective, Open Label and Multicentric Clinical Trial to Determine the Recommended Dose (Phase I) and Efficacy of Pazopanib in Combination With Interferon Alfa 2-A (Phase II), in Patients With Advanced Renal Cell Carcinoma
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 24 Dec 2023
Price :
$35
*
At a glance
- Drugs Interferon alpha-2a (Primary) ; Pazopanib (Primary)
- Indications Advanced breast cancer; Endometrial cancer; Haemangiosarcoma; Liposarcoma; Malignant melanoma; Mesothelioma; Ovarian cancer; Peritoneal cancer; Renal cell carcinoma; Sarcoma; Uterine cancer
- Focus Adverse reactions; Therapeutic Use
- 16 Mar 2020 Status changed from active, no longer recruiting to completed.
- 14 Feb 2019 Planned End Date changed from 1 Oct 2018 to 1 Mar 2019.
- 08 Oct 2018 Planned End Date changed from 1 Jun 2018 to 1 Oct 2018.